Personalised 3D-Printed Mucoadhesive Gastroretentive Hydrophilic Matrices for Managing Overactive Bladder (OAB)
Open Access
- 28 February 2023
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (3) , 372
Abstract
Overactive bladder (OAB) is a symptomatic complex condition characterised by frequent urinary urgency, nocturia, and urinary incontinence with or without urgency. Gabapentin is an effective treatment for OAB, but its narrow absorption window is a concern, as it is preferentially absorbed from the upper small intestine, resulting in poor bioavailability. We aimed to develop an extended release, intragastric floating system to overcome this drawback. For this purpose, plasticiser-free filaments of PEO (polyethylene oxide) and the drug (gabapentin) were developed using hot melt extrusion. The filaments were extruded successfully with 98% drug loading, possessed good mechanical properties, and successfully produced printed tablets using fused deposition modelling (FDM). Tablets were printed with varying shell numbers and infill density to investigate their floating capacity. Among the seven matrix tablet formulations, F2 (2 shells, 0% infill) showed the highest floating time, i.e., more than 10 h. The drug release rates fell as the infill density and shell number increased. However, F2 was the best performing formulation in terms of floating and release and was chosen for in vivo (pharmacokinetic) studies. The pharmacokinetic findings exhibit improved gabapentin absorption compared to the control (oral solution). Overall, it can be concluded that 3D printing technology is an easy-to-use approach which demonstrated its benefits in developing medicines based on a mucoadhesive gastroretentive strategy, improving the absorption of gabapentin with potential for the improved management of OAB.Keywords
This publication has 67 references indexed in Scilit:
- Applications of poly(ethylene oxide) in controlled release tablet systems: a reviewDrug Development and Industrial Pharmacy, 2013
- Gabapentin: A novel drug as add-on therapy in cases of refractory overactive bladder in childrenJournal of Pediatric Urology, 2013
- Which anticholinergic drug for overactive bladder symptoms in adultsCochrane Database of Systematic Reviews, 2012
- Optimization of a Dual Mechanism Gastrofloatable and Gastroadhesive Delivery System for Narrow Absorption Window DrugsAAPS PharmSciTech, 2011
- Incidence and Resolution Rates of Different Types of Urinary Incontinence in Women: Findings From a Cohort StudyJournal of Urology, 2011
- An international urogynecological association (IUGA)/international continence society (ICS) joint report on the terminology for female pelvic floor dysfunctionNeurourology and Urodynamics, 2009
- Prospective pharmacologic therapies for the overactive bladderTherapeutic Advances in Urology, 2009
- The neurogenic bladder: medical treatmentPediatric Nephrology, 2008
- Gabapentin: A Ca2+ channel alpha2-delta ligand far beyond epilepsy therapyDrugs of Today, 2008
- Mechanisms of Disease: involvement of the urothelium in bladder dysfunctionNature Reviews Endocrinology, 2007